

Effect of Tianeptine on Depressed Tinnitus Patients

Soo Min Hwang¹, Sae Hee Lim¹, Dong Ju Oh¹, Sung Kyun Kim²,
Hak Hyun Jung¹, and Gi Jung Im¹

¹Department of Otolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul,

²Department of Otolaryngology-Head and Neck Surgery, Hallym University College of Medicine, Hwaseong, Korea

Received April 28, 2016

Revised June 27, 2016

Accepted July 29, 2016

Address for correspondence

Gi Jung Im, MD, PhD

Department of Otolaryngology-

Head and Neck Surgery,

Korea University College of Medicine,

73 Incheon-ro, Seongbuk-gu,

Seoul 02841, Korea

Tel +82-2-920-5486

Fax +82-2-925-5233

E-mail logopas@korea.ac.kr

Background and Objectives: Tianeptine is a tricyclic antidepressant that has a novel pharmacological property: it increases the reuptake of 5-hydroxytryptamine. Recent studies have reported that the prevalence of depression is greater in patients with tinnitus than in control subjects who do not have tinnitus. The purpose of this study was to assess the efficacy of tianeptine for the relief of tinnitus, especially in patients with depressive mood.

Subjects and Methods: Among a total of 52 tinnitus patients, 15 had depressive mood. The depressed tinnitus patients were prescribed Stablon® 12.5 mg once daily for 1 month without any other drug. We assessed the severity of tinnitus, level of depression, and the quality of sleep in these patients by using the Tinnitus Handicap Inventory (THI), Beck Depression Inventory (BDI), and Pittsburgh Sleep Quality Index (PSQI). Hearing impairment and severity of tinnitus were measured with pure tone audiometry, speech audiometry, and tinnitograms. These evaluations were conducted before and after medication treatment.

Results: For the 15 depressed tinnitus patients, THI scores significantly correlated with BDI and PSQI scores prior to medication treatment. These results showed that the discomfort of tinnitus was closely related to depression and sleep disorder. After medication treatment, THI and BDI scores significantly decreased, indicating that tinnitus and depression improved. However, no significant alteration in PSQI score was observed, indicating that there was no improvement in sleep quality. **Conclusions:** In the treatment of depressed tinnitus patients, tianeptine might be an efficient drug to treat both tinnitus and depression. However, tianeptine is unlikely to improve the quality of sleep in these patients.

J Audiol Otol 2016;20(2):90-96

KEY WORDS: Tianeptine · Tinnitus · Depression · Sleep disorder.

Introduction

Tianeptine is not a typical antidepressant drug; chemically, it is a tricyclic antidepressant (TCA); however, it possesses the pharmacological property of increasing 5-hydroxytryptamine uptake. As a result of this mechanism, tianeptine has a faster onset of antidepressant effect, better efficacy among selective serotonin reuptake inhibitors (SSRIs) [1], and fewer adverse effects than typical tricyclic antidepressants and SSRIs do [2]. Several pre-clinical studies have revealed that

tianeptine also has a beneficial effect on depression and various stress-induced disorders [3,4].

Tinnitus is the phantom perception of sound that results from activity within the nervous system without any corresponding mechanical or vibratory activity within the cochlea, and is not related to any external stimuli [5]. It is estimated that one-third of the global population experiences tinnitus at least once in their lifetime, and about 1–5% of these affected individuals experience serious psychosocial complications [6]. Recent studies have reported that tinnitus patients are likely to have comorbid psychological disorders including depression and anxiety [7,8], and show a high prevalence of depression [9,10]. In addition, the severity of tinnitus has been positively correlated with levels of depression [11-13].

There is no definite cure for tinnitus. Management of tinni-

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

tus requires a multi-disciplinary approach depending on the cause and comorbid conditions of tinnitus patients. Currently, there are no FDA-approved drugs to treat tinnitus, however, clinical studies are underway to evaluate the efficacy of N-methyl-d-aspartate and dopamine D2 antagonists, SSRIs, and γ -aminobutyric acid (GABA) agonists [14]. Previous studies suggest that patients with severe depression may experience improvement in their tinnitus after treatment with antidepressants such as nortriptyline [15] or sertraline [16].

In this study, we investigated the relationship among the severity of tinnitus, the level of depression, and the quality of sleep in depressed tinnitus patients. We also evaluated the efficacy of tianeptine on treating tinnitus with depressive mood.

Subjects and Methods

Patients

A total of 52 patients who visited the otorhinolaryngology outpatient clinic of tertiary hospital from 2009 through 2014 and were first diagnosed as having tinnitus with were prospectively investigated. All patients underwent history interviews, physical examinations, hearing tests, and answered questionnaires. Questionnaires on tinnitus, depression symptoms, and quality of sleep were completed at the first visit. Patients with acute tinnitus (<3 month), otologic disease, history of previous treatment for tinnitus or systemic disease (Hypertension, diabetic mellitus or cardiovascular disease) were excluded.

The patient provided written informed consent to participate in this study, which was approved by the local Institutional Review Board for Research (ED15142-3).

Evaluation of depression symptoms and study design

The Korean version of the Beck Depression Inventory (BDI) was used to evaluate the severity of depression symptoms in patients. It comprises 21 questions, which includes the emotional, cognitive, motive, and physiological areas of depression. Each question is rated on a scale from 0 to 3, depending on the degree of symptom, and the total score is calculated from a range of 0 to 63. A previous study found that a BDI score of 16 or above for men, and 17 or above for women is classified as depression [17]. Based on these criteria, tinnitus patients were divided into two groups: the control group and the depressed group.

Medication

History taking, physical examinations, questionnaires, and hearing tests were performed in 52 tinnitus patients. Of these, only 15 patients had depressive mood according to the Kore-

an-version BDI. These depressed tinnitus patients were administered tianeptine (Stablon[®], JEIL, Seoul, Korea) 12.5 mg once daily for 1 month with no other medications. Patients revisited out-patient clinic with 2 weeks, 4 weeks. Evaluations for tinnitus, depression, and quality of sleep were conducted before and after medication use.

Evaluation of tinnitus

To evaluate the severity of tinnitus, the Tinnitus Handicap Inventory (THI) was administered to patients. The Korean-version THI measures the impact of tinnitus on daily life and its reliability and validity were proven through a previous study [18]. It contains 25 items with a functional subscale (11 items), emotional subscale (9 items), and catastrophic subscale (5 items). Each question is rated as 0 (none), 2 (sometimes), or 4 (always). The total score is calculated from a range of 0 to 100.

Evaluation of sleep quality

The Korean version of the Pittsburgh Sleep Quality Index (PSQI) was used to assess the quality of sleep [19]. It comprises 19 items, which measure subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime function. Each question is rated from a scale of 0 to 3 depending on the degree of symptoms, and the total score is calculated from a range of 0 to 21. A total score of 5 or above indicates poor sleep quality.

Hearing test

Pure tone audiometry, speech audiometry, and tinnitograms were performed to check for hearing and tinnitus status of patients.

Statistical analysis

Statistical analysis was performed using the SPSS 21.0 (SPSS Inc., Chicago, IL, USA) program. The Pearson bivariate correlation test was used to analyze correlations between variables. Qualitative variables were analyzed using Fisher's exact test to compare differences between groups. A paired sample t-test was used to compare changes in THI, BDI, and PSQI scores before and after the medication use. All data were expressed as means \pm standard deviation. The level of statistical significance was set as $p < 0.05$.

Results

Characteristics of depressed tinnitus patients

A total of 52 tinnitus patients were diagnosed as having

tinnitus. According to the BDI score criteria, tinnitus patients were stratified into two groups according to the presence of depressive mood. Thirty-seven (71.2%) patients without depressive mood were in the control tinnitus group and 15 (28.8%) patients with depressive mood were in the depressed tinnitus group. As shown in Table 1, more female patients were observed in the depressed tinnitus group, which was statistically significant ($p=0.031$). The mean THI score of the depressed tinnitus group was $51.67 (\pm 19.58)$, which was significantly higher than that in the control tinnitus group ($p=0.005$).

Table 1. Characteristics of tinnitus patients

	Tinnitus patients		p-value [§]
	Control (n=37)	Depressed (n=15)	
Gender			0.031*
F	20 (54.1)	13 (86.7)	
M	17 (45.9)	2 (13.3)	
Grade			0.192
1	11 (29.7)	1 (6.7)	
2	11 (29.7)	4 (26.7)	
3	10 (27.0)	4 (26.7)	
4	3 (8.1)	4 (26.7)	
5	2 (5.4)	2 (13.3)	
AGE	56.70 ± 12.57	58.60 ± 10.75	0.471
PTA	30.92 ± 19.10	34.50 ± 16.56	0.385
THI	32.54 ± 22.15	51.67 ± 19.58	0.005 [†]
PSQI	6.86 ± 4.92	8.20 ± 4.06	0.055
BDI	8.00 ± 2.44	25.27 ± 6.14	<0.001 [†]

More female patients were observed in the depressed tinnitus group, which was statistically significant ($*p=0.031$). The mean THI score of the depressed tinnitus group was $51.67 (\pm 19.58)$, which was significantly higher than that in the control tinnitus group ($^{\dagger}p<0.005$). No significant differences in the severity of tinnitus, age, pure tone audiometry, and PSQI score were found. $*$ significant result at the 0.05 level, † at the 0.01 level, ‡ at the 0.001 level, § Fisher's exact test or Student's t-test. PTA: pure tone audiometry, THI: Tinnitus Handicap Inventory, PSQI: Pittsburgh Sleep Quality Index, BDI: Beck Depression Inventory

No significant differences in the severity of tinnitus, age, pure tone audiometry and PSQI score were found.

Correlation among THI, BDI, PSQI in depressed tinnitus patients

Next, we investigated the relationship among THI, BDI, PSQI scores in depressed tinnitus patients. Table 2 shows correlations of depressed tinnitus patients based on THI and BDI scores, THI and PSQI scores, and BDI and PSQI scores, respectively. There was a significant correlation between THI and BDI scores ($r=0.5758, p=0.0247$) (Fig. 1) and between THI and PSQI scores ($r=0.6151, p=0.0147$) (Fig. 2). However, there was no significant correlation between BDI and PSQI scores in depressed tinnitus patients (Table 2).

Effects of tianeptine on THI, BDI, and PSQI scores in depressed tinnitus patients

To evaluate the efficacy of tianeptine on tinnitus, depression symptoms, and the quality of sleep, 15 depressed tinnitus patients were administered tianeptine (Stablon[®]) 12.5 mg once daily at bedtime for 1 month and were evaluated for the severity of tinnitus, THI, BDI, and PSQI scores before and after medication treatment. After medication treatment, the mean score of THI improved from $51.67 (\pm 19.58)$ to $43.07 (\pm 18.68)$ and those of BDI improved from $24.71 (\pm 6.13)$ to $15.53 (\pm 4.10)$, which were statistically significant ($p=0.0031, p<0.001$, respectively). Tianeptine had no significant improvement on the PSQI score (Table 3). Furthermore, Table 4, 5 show the improved score of each item of THI and BDI, respectively, with tianeptine treatment. The functional subscale and emotional scale of THI score was significantly improved with tianeptine treatment ($p=0.020, p=0.012$) (Table 4). Interestingly, the mean PSQI score was not significantly altered after tianeptine treatment but an item of sleep latency significantly improved ($p=0.023$) (Table 6).




Fig. 1. Correlation between THI and BDI in depressed tinnitus patients. There was a significant correlation between THI and BDI scores ($r=0.5758, p=0.0247$). THI: Tinnitus Handicap Inventory, BDI: Beck Depression Inventory.




Fig. 2. Correlation between THI and PSQI in depressed tinnitus patients. There was a significant correlation between THI and PSQI scores ($r=0.6151$, $p=0.0147$). THI: Tinnitus Handicap Inventory, PSQI: Pittsburgh Sleep Quality Index.

Table 2. Correlation between THI, PSQI, and BDI scores in depressed tinnitus patients

		Depressed Tinnitus patients (n=15)
THI vs. BDI	Correlation coefficient (r)	0.5758
	p-value	0.0247*
THI vs. PSQI	Correlation coefficient (r)	0.6151
	p-value	0.0147*
BDI vs. PSQI	Correlation coefficient (r)	0.5
	p-value	0.0577

There was a significant correlation between THI and BDI scores ($r=0.5758$, $*p=0.0247$), and between THI and PSQI scores ($r=0.6151$, $*p=0.0147$). However, there was no significant correlation between BDI and PSQI scores in depressed tinnitus patients (p -value=0.0577). *significant correlation at the 0.05 level. THI: Tinnitus Handicap Inventory, PSQI: Pittsburgh Sleep Quality Index, BDI: Beck Depression Inventory

Table 3. THI and BDI scores in tinnitus patients after tianeptine treatment

	Depressed tinnitus patients (n=15)		p-value [§]
	Pre-treatment (mean ± SD)	Post-treatment (mean ± SD)	
THI	51.67 ± 19.58	43.07 ± 18.68	0.0031 [†]
THI grade	3.07 ± 1.18	2.80 ± 0.94	0.3343
BDI	24.71 ± 6.13	15.53 ± 4.10	<0.001 [†]
PSQI	8.36 ± 4.06	7.47 ± 5.15	0.6175

After medication treatment, the mean score of THI improved from 51.67 (± 19.58) to 43.07 (± 18.68) and those of BDI improved from 24.71 (± 6.13) to 15.53 (± 4.10), which were statistically significant ($*p=0.0031$, $†p<0.001$, respectively). Tianeptine had no significant improvement on the PSQI score. *significant result at the 0.05 level, [†]at the 0.01 level, [‡]at the 0.001 level, [§]Fisher's exact test or Student's t-test. THI: Tinnitus Handicap Inventory, BDI: Beck Depression Inventory, PSQI: Pittsburgh Sleep Quality Index

Discussion

There is a 5% prevalence of major depression in the public and it is reported that the probability of depression occurring at least once in a lifetime is 20% in women, and 10–15% in men [20]. Tinnitus is a common symptom with 10–15% prevalence in the general population, and it negatively affects 1–2% of these individuals during normal activities. According to previous reports, approximately 39% of tinnitus patients also have major depression [21]. In our study, 15 (28.8%) of 52 tinnitus patients showed a propensity for depressive mood compared to control patients. The reason for the higher percentage of depressive mood in women who have tinnitus is that they have greater predisposition to depression than men, which has a high impact according to the prevalence of depression. However, there was a higher proportion of women with tinnitus who visited the hospital for treatment. Furthermore, according to the threshold of predisposition to depression, which was 17 points in women and 16 points in men

from The Study on Standardization of BDI, women usually have more depression symptoms than men.

The aims of this study were to prove the correlation between tinnitus and depression and to investigate a beneficial effect of treating tinnitus patients with depressive mood. Particularly, in depressed tinnitus patients, THI scores were positively correlated with PSQI and BDI scores with statistical significance. These results show that the discomfort of tinnitus, depression, and sleep disorders were closely related. Next, tianeptine significantly improved tinnitus (total THI score), depression (total BDI score), and sleep latency in depressed tinnitus patients. However, there was no statistically significant improvement in the quality of sleep (total PSQI score). Based on the results of this study, tianeptine might be an efficient mediation to treat both tinnitus and depression symptoms in tinnitus patients with depressive mood. We could consider the order-relationship of depression and tinnitus in depressed tinnitus patients. Dobie, et al. [22] reported that more than 50 percent of tinnitus patients already had

major depressive disorder before the occurrence of tinnitus. Only 7% of depressed patients had tinnitus before being diagnosed for depression [23]. In other words, patients with depression are more likely to experience tinnitus. When reviewing other reports, tinnitus is not an independent factor to trigger depression, but it can be an important factor in patients with sensitivity to mental illness. There is no proof that depression can directly cause tinnitus. There was no significant difference between patients with depression and those without [20]. However, people with depression sometimes have an inadequate physical response, therefore, the tinnitus, which was previously ignored, may feel worse [24]. The key factor in explaining why some tinnitus patients feel a little

Table 4. THI scores of depressed tinnitus patients after tianeptine treatment

	Mean		Diff.	p-value [§]
	Pre-Tx.	Post-Tx.		
THI total score	51.67	43.07	8.600	0.003 [†]
Grade	3.13	2.80	0.333	0.334
Functional subscale	20.73	17.67	3.067	0.020*
1F	2.40	2.27	0.400	0.082
2F	1.60	1.20	-0.267	0.334
4F	1.33	1.60	0.533	0.164
7F	2.27	1.73	-1.000	0.019*
9F	1.33	1.20	0.667	0.019*
12F	2.20	2.13	-0.400	0.189
13F	1.47	1.20	-0.267	0.499
15F	1.60	1.20	0.467	0.204
18F	1.47	1.47	0.933	0.017*
20F	2.27	1.80	0.133	0.719
24F	2.80	1.87	0.400	0.082
Emotional subscale	19.33	15.33	4.000	0.012*
3E	2.27	2.00	0.267	0.164
6E	2.67	2.67	0.000	1.000
10E	1.60	1.47	0.133	0.751
14E	2.53	1.80	0.733	0.036*
16E	2.13	1.60	0.533	0.104
17E	1.73	1.60	0.133	0.719
21E	2.13	1.33	0.800	0.047*
22E	2.40	1.33	1.067	0.001 [†]
25E	1.87	1.53	0.333	0.238
Catastrophic subscale	11.60	10.07	1.533	0.182
5C	2.00	1.67	0.333	0.238
8C	2.13	2.27	0.133	0.670
11C	3.07	2.53	0.533	0.041*
19C	1.73	1.73	0.000	1.000
23C	2.67	1.87	0.800	0.009 [†]

*significant result at the 0.05 level, [†] at the 0.01 level, [‡] at the 0.001 level, [§]Fisher's exact test or Student's t-test. 7F: Disturbance of sleep, 9F: Social activities, 18F: Ignorance of tinnitus, 14E: Irritability, 21E: Depressive mood, 22E: Anxious feeling, 11C: Feeling of disease, 23C: Surmounting tinnitus. THI: Tinnitus Handicap Inventory, Pre-Tx.: pre-treatment, Post-Tx.: post-treatment, Diff.: difference

discomfort while others are distressed is the psychological aspect associated with depression. As such, since depression has a higher associated morbidity and a close relationship

Table 5. BDI scores of depressed tinnitus patients after tianeptine treatment

	Mean		Diff.	p-value [§]
	Pre-Tx.	Post-Tx.		
BDI total score	25.27	15.53	9.733	0.000 [†]
1	2.00	2.13	-0.133	0.499
2	2.87	2.67	0.200	0.384
3	1.73	1.60	0.133	0.334
4	2.53	2.00	0.533	0.015*
5	1.67	1.40	0.267	0.104
6	1.73	1.47	0.267	0.164
7	2.73	1.47	1.267	0.000 [†]
8	2.93	1.47	1.467	0.000 [†]
9	1.67	1.40	0.267	0.104
10	1.27	1.27	-	-
11	1.67	1.47	0.200	0.271
12	2.13	2.07	0.067	0.719
13	2.53	1.93	0.600	0.003 [†]
14	2.33	1.53	0.800	0.005 [†]
15	2.53	1.27	1.267	0.001 [†]
16	2.73	1.60	1.133	0.000 [†]
17	2.33	1.60	0.733	0.006 [†]
18	1.87	1.60	0.267	0.364
19	1.47	1.33	0.133	0.546
20	2.47	2.20	0.267	0.262
21	3.07	3.07	-	-

*significant result at the 0.05 level, [†] at the 0.01 level, [‡] at the 0.001 level, [§]Fisher's exact test or Student's t-test. 4: Satisfaction, 7: Disappointment in myself, 8: To blame myself for something, 13: Making decision, 14: Feeling of appearance, 15: Efficiency of work, 16: Sleep, 17: Tiredness. BDI: Beck Depression Inventory, Pre-Tx.: pre-treatment, Post-Tx.: post-treatment, Diff.: difference

Table 6. PSQI scores of depressed tinnitus patients after tianeptine treatment

	Mean		Diff.	p-value [†]
	Pre-Tx.	Post-Tx.		
PSQI total score	8.20	7.47	0.733	0.617
Sleep quality	1.73	1.00	0.733	0.060
Sleep latency	1.80	1.20	0.600	0.023*
Sleep duration	1.13	1.40	-0.267	0.301
Sleep-wake patterns	0.40	0.53	-0.133	0.698
Sleep disturbance	1.60	1.67	-0.067	0.719
Use of sleep medication	0.60	0.60	0.000	1.000
Daytime consequences	0.93	1.07	-0.133	0.634

The mean PSQI score was not significantly altered after tianeptine treatment but an item of sleep latency significantly improved (*p=0.023). *significant result at the 0.05 level, [†]Fisher's exact test or Student's t-test. PSQI: Pittsburgh Sleep Quality Index, Pre-Tx.: pre-treatment, Post-Tx.: post-treatment, Diff.: difference

with tinnitus, it is possible to administer antidepressants for the treatment of tinnitus [21].

In the past, a number of studies reported on tinnitus treatment with TCAs [20,22,25]. Recent studies focus on SSRIs, which have less adverse effects than TCAs. In a study of severe tinnitus accompanied with depression, administration of sertraline showed meaningful improvement of tinnitus compared to placebo [21]. After tinnitus with depression was treated with different types of SSRIs, improvement of tinnitus was reported [26]. The mechanism of the effects of antidepressants on tinnitus has not yet been established. The main hypothesis is that antidepressants may not directly affect tinnitus, but the depression accompanied with tinnitus. This is supported by the fact that in patients with severe depression, their subjective tinnitus improved with treatment with nortriptyline [15,27]. Furthermore, patients with depression may be more sensitive to internal or external noise than those without depression [22]. Another hypothesis is that SSRIs can reduce tinnitus symptoms directly by interfering with the transmission of tinnitus impulses [28]. This is supported by a number of documents that there are a large number of serotonin receptors in the auditory nervous system and variation of these receptors can generate auditory evoked potential [29,30]. In some reports, antidepressants, including TCAs and SSRIs, can cause tinnitus as a side effect in some patients [16], but the tinnitus was reversible when the drugs were stopped. Tinnitus treatment with antidepressants, as current studies have shown, is considered to be the most effective to use in tinnitus patients with depression.

This paper is a prospective study that observed an improvement in tinnitus by treatment with tianeptine alone in tinnitus patients with depressive mood. We look forward to a choice of new drugs for the treatment of tinnitus in the ENT area. Tianeptine is a good treatment of choice in severe tinnitus patients with depressive mood, but they cannot control sleep disorders. Therefore, it can be helpful to co-administer with sedatives or hypnotics that are not addictive.

In this study, there was no control group using other antidepressants or placebo. We need clinical studies examining a larger number of patients for a long period and comparing medications including other antidepressants, blood circulation enhancers or tranquilizers to investigate relative efficacy of tianeptine.

In conclusion, tianeptine is good alternative treatment in depressed tinnitus patients because it is an effective agent to reduce both symptoms. In this case, additional treatments are required to control sleep disorders.

Acknowledgments

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2014-071497; R1429733); Korea University research grant (K1609821); and Korea Health Industry Development Institute (R1606511). These funding sources only provided financial support and played no specific scientific role in this study.

Conflicts of interest

The authors have no financial conflicts of interest.

REFERENCES

- 1) Woo YS, Bahk WM, Jeong JH, Lee SH, Sung HM, Pae CU. Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy. *Psychiatry Clin Neurosci* 2013;67: 219-27.
- 2) McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. *Mol Psychiatry* 2010;15:237-49.
- 3) Curzon G, Kennett GA, Sarna GS, Whitton PS. The effects of tianeptine and other antidepressants on a rat model of depression. *Br J Psychiatry Suppl* 1992;(15):51-5.
- 4) Kelly JP, Leonard BE. The effect of tianeptine and sertraline in three animal models of depression. *Neuropharmacology* 1994;33: 1011-6.
- 5) Jastreboff PJ. Phantom auditory perception (tinnitus): mechanisms of generation and perception. *Neurosci Res* 1990;8:221-54.
- 6) Martines F, Bentivegna D, Di Piazza F, Martines E, Sciacca V, Martinciglio G. Investigation of tinnitus patients in Italy: clinical and audiological characteristics. *Int J Otolaryngol* 2010;2010:265861.
- 7) Reynolds P, Gardner D, Lee R. Tinnitus and psychological morbidity: a cross-sectional study to investigate psychological morbidity in tinnitus patients and its relationship with severity of symptoms and illness perceptions. *Clin Otolaryngol Allied Sci* 2004;29:628-34.
- 8) Adoga AA, Adoga AS, Obindo JT. Tinnitus and the prevalence of co-morbid psychological stress. *Niger J Med* 2008;17:95-7.
- 9) Pinto PC, Marcelos CM, Mezzasalma MA, Osterne FJ, de Melo Tavares de Lima MA, Nardi AE. Tinnitus and its association with psychiatric disorders: systematic review. *J Laryngol Otol* 2014;128: 660-4.
- 10) Zöger S, Svedlund J, Holgers KM. Relationship between tinnitus severity and psychiatric disorders. *Psychosomatics* 2006;47:282-8.
- 11) Andersson G, Vretblad P, Larsen HC, Lyttkens L. Longitudinal follow-up of tinnitus complaints. *Arch Otolaryngol Head Neck Surg* 2001;127:175-9.
- 12) Holgers KM, Erlandsson SI, Barrenäs ML. Predictive factors for the severity of tinnitus. *Audiology* 2000;39:284-91.
- 13) Folmer RL. Long-term reductions in tinnitus severity. *BMC Ear Nose Throat Disord* 2002;2:3.
- 14) Salvi R, Lobarinas E, Sun W. Pharmacological treatments for tinnitus: new and old. *Drugs Future* 2009;34:381-400.
- 15) Sullivan M, Katon W, Russo J, Dobie R, Sakai C. A randomized trial of nortriptyline for severe chronic tinnitus. Effects on depression, disability, and tinnitus symptoms. *Arch Intern Med* 1993;153:2251-9.
- 16) Robinson SK, Viirre ES, Stein MB. Antidepressant therapy in tinnitus. *Hear Res* 2007;226:221-31.
- 17) Rhee MK, Lee YH, Park SH, Sohn CH, Chung YC, Hong SK, et al. A standardization study of Beck Depression Inventory I Korean version (K-BDI): reliability and factor analysis. *Korean J Psychopathol* 1995;4:77-95.
- 18) Kim JH, Lee SY, Kim CH, Lim SL, Shin JN, Chung WH, et al. Reliability and Validity of a Korean Adaptation of the Tinnitus Handi-

- cap Inventory. *Korean J Otolaryngol-Head Neck Surg* 2002;45:328-34.
- 19) Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193-213.
 - 20) Folmer RL, Griest SE, Meikle MB, Martin WH. Tinnitus severity, loudness, and depression. *Otolaryngol Head Neck Surg* 1999;121:48-51.
 - 21) Zöger S, Svedlund J, Holgers KM. The effects of sertraline on severe tinnitus suffering--a randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol*. 2006;26:32-9.
 - 22) Dobie RA, Sullivan MD, Katon WJ, Sakai CS, Russo J. Antidepressant treatment of tinnitus patients. Interim report of a randomized clinical trial. *Acta Otolaryngol* 1992;112:242-7.
 - 23) Zöger S, Svedlund J, Holgers KM. Psychiatric disorders in tinnitus patients without severe hearing impairment: 24 month follow-up of patients at an audiological clinic. *Audiology* 2001;40:133-40.
 - 24) Dobie RA. Depression and tinnitus. *Otolaryngol Clin North Am* 2003;36:383-8.
 - 25) Bayar N, Böke B, Turan E, Belgin E. Efficacy of amitriptyline in the treatment of subjective tinnitus. *J Otolaryngol* 2001;30:300-3.
 - 26) Folmer RL, Shi YB. SSRI use by tinnitus patients: interactions between depression and tinnitus severity. *Ear Nose Throat J* 2004;83:107-8, 110, 112 passim.
 - 27) Dobie RA, Sakai CS, Sullivan MD, Katon WJ, Russo J. Antidepressant treatment of tinnitus patients: report of a randomized clinical trial and clinical prediction of benefit. *Am J Otol* 1993;14:18-23.
 - 28) Shea JJ, Emmett JR, Orchik DJ, Mays K, Webb W. Medical treatment of tinnitus. *Ann Otol Rhinol Laryngol* 1981;90(6 Pt 1):601-9.
 - 29) Gallinat J, Senkowski D, Wernicke C, Juckel G, Becker I, Sander T, et al. Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing. *Neuropsychopharmacology* 2003;28:530-2.
 - 30) Simpson JJ, Davies WE. A review of evidence in support of a role for 5-HT in the perception of tinnitus. *Hear Res* 2000;145:1-7.